Multiple biochemical pathways were shown to be affected, such as cell cycle control, apoptosis, and angiogenesis.[42] In another recent publication, enzastaurin has been shown to be able to reverse acquired resistance to gefitinib, an EGFR small molecule inhibitor; while this study evaluated cell lines that are not NSCLC (colon cancer and prostate cancer), the mechanism observed may likely be observed in NSCLC.[43] The efficacy of combination enzastaurin and other cytotoxic agents in NSCLC might be dependent upon the schedule by which these drugs are delivered. This evidence concerns the gene EGFR and prostate cancer.